Cargando…

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients

Background: Clostridioides difficile infection (CDI) is a major source of morbidity and mortality. Even after recovery, recurrent CDI (rCDI) occurs frequently, and concomitant antibiotic use for treatment of a concurrent non–C. difficile infection is a major risk factor. Treatment with fidaxomicin v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, A. Krishna, Zhao, Qianzi, Krishnan, Jay, Bell, Justin, Henig, Oryan, Daniel, Jolene, Sawaya, Kara, Albin, Owen, Mills, John, Petty, Lindsay, Gregg, Kevin, Kaul, Daniel, Malani, Anurag, Pogue, Jason, Kaye, Keith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	C. Difficile
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615000/ http://dx.doi.org/10.1017/ash.2022.195

Ejemplares similares

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

Clostridioides difficile: A diagnostic intervention
por: Alsoubani, Majd, et al.
Publicado: (2022)

Clostridioides difficile Is Not Difficult to Predict in Hospital Settings
por: Alexander, Kinta, et al.
Publicado: (2021)

Prospective audit and feedback of Clostridioides difficile PCR at the time of ordering increases appropriateness of testing
por: Tassone, Daniel, et al.
Publicado: (2022)

Clinical Characteristics and Fecal Microbiome in Recurrent Versus Nonrecurrent Clostridioides difficile Infection
por: Lanjewar, Swapnil, et al.
Publicado: (2021)

Evaluation of the genomic epidemiology and transmission of Clostridioides difficile infection across a community
por: Tesini, Brenda, et al.
Publicado: (2022)

Role of diagnostic stewardship in reducing healthcare facility-onset Clostridioides difficile infections
por: Shallal, Anita, et al.
Publicado: (2022)

Examining the impact of the COVID-19 pandemic on hospital-associated Clostridioides difficile infection
por: Ray, Michael, et al.
Publicado: (2023)

Did Clostridioides difficile Testing and Infection Rates Change During the COVID-19 Pandemic?
por: Hawes, Armani, et al.
Publicado: (2021)

Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
por: Tran, Martin Tuan, et al.
Publicado: (2022)

Characteristics of antibiotic exposures for surgical procedures prior to Clostridioides difficile diagnosis—Minnesota, 2018
por: D’Heilly, Paige, et al.
Publicado: (2022)

Impact of Two-Step Testing Algorithm on Reducing Hospital-Onset Clostridioides difficile Infections
por: Navalkele, Bhagyashri, et al.
Publicado: (2021)

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
por: McGovern, Barbara, et al.
Publicado: (2021)

Impact of early identification of patients meeting testing criteria for Clostridioides difficile on standard infection ratios
por: Krier, Brad, et al.
Publicado: (2023)

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
por: Cohen, Stuart, et al.
Publicado: (2022)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

Effects of a hard stop for C. difficile testing: Provider uptake and patient outcomes
por: Doughman, Danielle, et al.
Publicado: (2023)

In veteran outpatients, antibiotics remain significant risk factor for community-acquired Clostridiodes difficile infection
por: Akpoji, Ukwen, et al.
Publicado: (2022)

Impact of exposure to potentially contaminated hospital beds on risk of hospital-onset C. difficile infection
por: Witt, Lucy, et al.
Publicado: (2022)

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
por: Sims, Matthew, et al.
Publicado: (2023)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile
por: Huhulescu, Steliana, et al.
Publicado: (2011)

Did Clostridioides difficile testing and infection rates change during the COVID-19 pandemic?
por: Hawes, Armani Minasian, et al.
Publicado: (2021)

Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291
por: Buckley, Anthony M., et al.
Publicado: (2011)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
por: Whitney, Laura, et al.
Publicado: (2023)

A cortex-specific penicillin-binding protein contributes to heat resistance in Clostridioides difficile spores
por: Alabdali, Yasir Adil Jabbar, et al.
Publicado: (2021)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection
por: Heleno, Caio T, et al.
Publicado: (2021)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

Clostridioides difficile infection: curbing a difficult menace
por: Khanna, Sahil, et al.
Publicado: (2022)

Immune response against Clostridioides difficile and translation to therapy
por: Sehgal, Kanika, et al.
Publicado: (2021)

Epidemiology of community-acquired and recurrent Clostridioides difficile infection
por: Fu, Yichun, et al.
Publicado: (2021)

The interplay of Clostridioides difficile infection and inflammatory bowel disease
por: Sehgal, Kanika, et al.
Publicado: (2021)

668. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection in immunocompromised hosts, a single center study
por: Alsoubani, Majd, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a125u2e38vftq53j9bcv07ama6